|
2018 – A year of unprecedented challenges and opportunities for pharmaceutical regulatory systems |
Medicines for Europe |
25 Jan 2018 |
Health & Consumers |
|
Vigilance saves lives! More focus needed on sustainability and patient engagement |
Medicines for Europe |
24 Jan 2018 |
Health & Consumers |
|
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come |
Medicines for Europe |
18 Jan 2018 |
Health & Consumers, InfoSociety |
|
Brexit - Life Science Industry Joint Position Paper |
Medicines for Europe |
14 Dec 2017 |
Health & Consumers, UK in Europe |
|
European Commission launches: “What I need to know about Biosimilar Medicines - Information for patients”, in 23 EU languages |
Medicines for Europe |
29 Nov 2017 |
Health & Consumers |
|
Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit |
Medicines for Europe |
28 Nov 2017 |
Health & Consumers, UK in Europe |
|
Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation |
Medicines for Europe |
22 Nov 2017 |
Health & Consumers |
|
Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs |
Medicines for Europe |
18 Oct 2017 |
Health & Consumers |
|
Medicines for Europe announces new President, launches Access to Medicines campaign |
Medicines for Europe |
10 Oct 2017 |
Health & Consumers |
|
Medicines for Europe to join the ISPOR Issue Panel on value added medicines |
Medicines for Europe |
05 Oct 2017 |
Health & Consumers |
|
Addressing medicine shortages in Europe: Competition is crucial for patient access |
Medicines for Europe |
29 Sep 2017 |
Health & Consumers, Competition |
|
2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments |
Medicines for Europe |
12 Sep 2017 |
Health & Consumers |
|
Oncology, the new era for biosimilar medicines |
Medicines for Europe |
08 Sep 2017 |
Health & Consumers |
|
Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation |
Medicines for Europe |
05 Sep 2017 |
Health & Consumers |
|
Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health |
Medicines for Europe |
16 Jun 2017 |
Health & Consumers |
|
62% of Medicines Dispensed in Europe are Generic, according to IMS New Data |
Medicines for Europe |
15 Jun 2017 |
Health & Consumers |
|
EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access |
Medicines for Europe |
23 May 2017 |
Health & Consumers |
|
Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe |
Medicines for Europe |
09 May 2017 |
Health & Consumers |
|
Medicines for Europe can contribute much more to improve healthcare sustainability than described in the OECD “Health at a Glance 2016” report |
Medicines for Europe |
24 Nov 2016 |
Health & Consumers |
|
Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market |
Medicines for Europe |
19 Sep 2016 |
Health & Consumers |
